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Introduction / Background 
While the majority of malignancies are diagnosed in the elderly population, 10% of 
malignancies are diagnosed in young patients before they have had the opportunity to have 
children and start a family. While incidence of cancer in a younger population is increasing, long 
term survival is also increasing.1 However, cancer treatments, such as chemotherapy and 
radiotherapy, often have a gonadotoxic effect on the ovaries of both prepubescent girls and 
women of childbearing age, leading to infertility. Premature ovarian failure (POF) occurs in 
anywhere from 20% to 80% of cancer patients, depending on the treatment provided, dosages, 
and the patients age.1 Because of the increasing survival rate of young women diagnosed with 
cancer, fertility preservation has been an increasingly important goal of treatment in oncology. 
There are multiple methods of fertility preservation that are common in cancer patients. 
One method that is frequently used is oocyte or embryo cryopreservation. In this process, a 
woman’s ovaries are stimulated so that multiple oocytes can be extracted. The oocytes can then 
be fertilized and frozen as embryos or frozen without fertilization. The procedure is commonly 
performed and considered to be a safe and effective method of preserving fertility.2 However, 
there is a newer, more experimental method of fertility preservation known as ovarian tissue 
cryopreservation. In this procedure, either tissue from one ovary or one whole ovary is removed 
surgically, typically via a laparoscopic approach. This tissue is then frozen and stored for 
reimplantation in the pelvis after gonadotoxic treatment has been completed.2 This procedure is 
still considered experimental and has not become a routinely used method of fertility 
preservation.2,3 This leads to the question: Among females with premature ovarian failure 
secondary to chemotherapy, how does ovarian tissue cryotherapy as a method of fertility 
preservation compare to oocyte cryopreservation, as measured by percentage of patients with 
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successful pregnancies after the procedure and return of ovarian function as determine by FSH 
level.   
Discussion 
Oocyte cryopreservation advantages and disadvantages 
Both oocyte cryopreservation and ovarian tissue cryopreservation have their advantages 
and disadvantages. Oocyte cryopreservation is a frequently utilized procedure and multiple 
studies have shown that it is a very effective method of fertility preservation. One study reported 
that a cohort of women who underwent oocyte cryopreservation and later had their eggs thawed, 
fertilized, and implanted had an ongoing and delivered pregnancy rate of 57%.4  
One advantage that oocyte cryopreservation has over ovarian tissue cryopreservation is 
that it is significantly less invasive. Oocyte harvesting for cryopreservation involves a needle 
inserted through the vaginal wall. When the patient is interested in pursuing pregnancy, the egg 
is then fertilized and inserted into the uterus through the cervix.2 Ovarian tissue cryopreservation, 
however, involves one surgery to harvest the tissue, and another surgery to implant the tissue 
into the pelvis.2 
Oocyte cryopreservation also has its downsides, particularly in patients who are looking 
to preserve fertility prior to treatment for malignancies. One major downside is that in can cause 
a delay in treatment for cancer patients. Follicles need to be stimulated in order to produce 
sufficient oocytes for harvesting, and that process takes time.1 This delay in cancer treatment, 
can be unacceptable in patients with aggressive malignancies that require immediate gonadotoxic 
treatment. Oocyte cryopreservation also cannot be used in prepubescent girls, meaning that 
ovarian tissue cryopreservation is the only fertility preservation treatment for girls diagnosed 
with cancer prior to menarche.1 Finally, if the cancer treatment results in ovarian failure, oocyte 
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cryopreservation cannot preserve ovarian function in patients who experience premature ovarian 
failure secondary to gonadotoxic treatment.5 This premature ovarian failure can lead to a long-
term need for hormone supplementation, especially in young women.  
Ovarian tissue cryopreservation advantages and disadvantages  
There are some advantages that ovarian tissue cryopreservation has over oocyte 
cryopreservation. One advantage is that there is significantly less delay in cancer treatment 
because the ovaries do not need to be stimulated prior to the procedure.5 This allows for fertility 
preservation without complicating the cancer treatment. One study showed that out of 92 cancer 
patients who underwent surgery for preservation of ovarian tissue, only two experienced a delay 
in their cancer treatment, secondary to minor surgical complications.6 Ovarian tissue 
cryopreservation is also the only option for fertility preservation in prepubescent girls, as their 
ovaries cannot be stimulated prior to menarche.2 Finally, ovarian tissue cryopreservation is the 
only option for patients who are looking for return of normal ovarian function and menstruation 
following gonadotoxic treatment. The goal of reimplantation of the frozen ovarian tissue is to 
allow the tissue to function as it did prior to removal. With this, normal hormonal regulation 
should return if the procedure is successful.  
Multiple studies have been done to determine the rate at which ovarian function actually 
returns. In one study,  all 13 patients who had ovarian tissue reimplanted experienced return of 
normal ovarian function for a period of at least five years after the procedure, as determined by a 
decline in levels of follicle stimulating hormone (FSH) following the procedure.5 Another study 
showed that after three ovarian tissue autotransplants were performed, one transplant stopped 
functioning after nine years and the other two were still functioning after a 7 year period of time 
based on FSH levels7.  
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In a larger study, 52 of 56 women had restoration of ovarian function following ovarian 
tissue autotransplantation,8 and in one final study, 12 women who underwent the procedure had 
ovarian function return between eight and 26 weeks, with a lifespan of ovarian function lasting 
between 6 months and still functioning after 54 months.9 Looking at all this data together, it is 
clear that autotransplantation of cryopreserved ovarian tissue provides a robust return of ovarian 
function in almost all patients. This allows for an improved quality of life in cancer patients 
following treatment due to return of normal menstruation and hormonal regulation, as well as 
preventing the need for hormone replacement therapy in the younger patients. No other method 
of fertility preservation allows for return of ovarian function following gonadotoxic treatment.  
Studies have also revealed that ovarian tissue cryopreservation is effective in allowing 
patients to become pregnant after reimplantation. In one smaller study ten of the 13 patients who 
underwent reimplantation of cryopreserved ovarian tissue became spontaneously pregnant at 
least once, resulting in 13 healthy babies and a 77% live birth rate.2 Another study showed that 
three of eight patients that had their ovarian tissue reimplanted had become pregnant, although 
the study did not have any information on the outcomes of the pregnancies.1 In yet another study, 
seven of 21 patients delivered healthy babies, resulting in a 33% live birth rate.10 Finally, one last 
study revealed that out of 60 patients who underwent autotransplantation of cryopreserved 
ovarian tissue, 11 patients have conceived and 6 had delivered 12 healthy babies, with two of the 
pregnancies ongoing at the time the study was published.8 These studies seem to confirm the 
efficacy of the procedure in returning fertility. However, the small sample size in most studies 
and the low overall return rate for reimplantation of cryopreserved ovarian tissue can make 
determining the true efficacy of ovarian tissue cryopreservation difficult.  
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Ovarian tissue cryopreservation has also been shown to be a very safe procedure.  One 
study showed that in 309 cases of ovarian tissue cryopreservation procedure, the procedure only 
resulted in minor complications, mainly bleeding.3 In another study of 545 patients who 
underwent ovarian tissue cryopreservation, only one patient had a major complication (intra-
abdominal hemorrhage).10 Not only is the procedure safe, but the patient satisfaction is very 
high. One study showed that 96% of patients were satisfied with the procedure, as determined by 
survey sent to patients who had undergone the procedure.10  
However, one major concern with the procedure in cancer patients is the small but real 
risk of reintroducing cancerous cells in the cryopreserved ovarian tissue after remission of the 
cancer. One study showed that ovarian metastases are most common in patients with leukemia, 
but less common in patients with most other cancers.11 Ovarian metastasis is also not seen at all 
in patients with breast cancer and lymphoma.11 In cancer patients considering ovarian tissue 
cryopreservation, it is important to consider the type of cancer the patient has and the risk of 
ovarian metastasis prior to recommending the procedure. It is also important to educate the 
patient of the risk of reintroduction of the cancer prior to the procedure, especially in cancers that 
have a high risk of ovarian metastasis.  
Conclusion 
Ovarian tissue cryopreservation is an exciting and effective method of fertility preservation 
in patients with premature ovarian failure secondary to cancer treatment. However, it may not be 
the right choice for healthy women trying to prolong fertility. The ideal patient to undergo 
ovarian tissue cryopreservation is a prepubescent or young woman recently diagnosed with 
breast cancer or lymphoma and interested in ensuring their ovarian function returns and they are 
able to preserve fertility prior to gonadotoxic therapies. The procedure is still considered 
 
 7 
experimental, but has been shown to be effective and safe in the right patient population. The 
procedure seems to be very effective based on the studies, but the poor rate of return for 
reimplantation of ovarian tissue and small sample size in most of the studies make it difficult to 
evaluate the true efficacy of ovarian tissue cryopreservation. 56 to 59 patients still haven’t 
utilized tissue in one study, with reasons ranging from still being in cancer treatment, social and 
personal reasons, or the patient passed away from cancer.7 However, the patient satisfaction with 
the procedure is high, and the chance to preserve ovarian function and fertility has the 
opportunity to significantly improve patient lives following cancer treatment and remission. 
Some future areas to investigate include performing larger studies to show the efficacy of the 
treatment. It would also be interesting to investigate usefulness as treatment for patients with 
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